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chiara.baratelli@gmail.comSummaryInsulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment of
the malignant NE disease of the pancreas deeply changed in the last years, thanks to the introduction of new target
molecules, as everolimus. Even if the exact mechanism is not actually known, one of the side effects of everolimus,
hyperglycemia, has been demonstrated to be useful to contrast the typical hypoglycemia of the insulinoma. We report the
case of a patient with a metastatic malignant insulinoma treated with intermittent everolimus, obtaining an important
improvement in the quality of life; this suggests the necessity of preclinical studies to analyze the cellular pathways involved
in insulin-independent gluconeogenesis.Learning points:
† Effect of somatostatin analogs is long-lasting in the control of functioning NE tumors.
† Persistent everolimus control of hypoglycemia despite serum insulin levels and disease progression.
† Open issue: are disease progression and the increase in serum markers the only valid criteria to reject a treatment?Background
Insulinoma is an uncommon insulin-secreting pancreatic
islet cell neuroendocrine (NE) tumor. Its estimated
incidence is approximately three to four cases per million
individuals per year. It can occur sporadically (w95%)
or constitute a part of multiple endocrine neoplasia type 1
(MEN1) or Von Hippel–Lindau syndrome (4–6%) (1).
Most insulinomas are benign (90% of cases); the mali-
gnant forms should be suspected when the tumor size exceeds
4 cm and when the tumor arises in the context of MEN1.
The treatment of the malignant form is challenging,
and especially, the management of the hypoglycemia
is difficult.There is limited evidence about the role of traditional
cytotoxic agents in the management of the syndrome,
whereas somatostatin analogs may control hypoglycemia
symptoms, and inhibit tumor progression in certain
disease settings (2).
Recently, a better understanding of molecular
pathways has provided clues for new therapeutic strategies
and a variety of targeted agents have been explored in
pancreatic NE tumors.
Everolimus, an inhibitor of the mechanistic target
of rapamycin (MTOR), was approved by the FDA in 2011
for the treatment of progressive pancreatic NE tumors (3).
This biological agent has been mostly employed after thehttp://www.edmcasereports.com
Published by Bioscientifica Ltd
C Baratelli and others Everolimus for treating
insulinoma patient
ID: 14-0047; September 2014
DOI: 10.1530/EDM-14-0047AUTHOR COfailure of somatostatin analogs and/or systemic chemo-therapies. However, everolimus may be considered earlier
in the course of treatment in presence of intolerability
or contraindication for other therapies.
In a recent study, everolimus was compared with
placebo in 410 patients with progressive well- to moder-
ately- differentiated pancreatic NE tumors. Everolimus
significantly prolonged disease-free interval by 6.4 months
compared with placebo, and this effect was long lasting
with 35% stabilizations at 18 months (4).
As the activation of the PI3K/AKT/MTOR pathway is
essential for inhibiting gluconeogenesis by insulin (5),
hyperglycemia is a frequent side effect of everolimus
therapy, and this finding makes the drug appealing to
manage insulinoma (6) (7). The exact mechanisms by
which everolimus can control hypoglycemia in patients
with insulinoma are not fully elucidated but are reportedly
independent of tumor regression (6).
In a recent small series, hypoglycemia improvement
after everolimus was associated with a reduction in serum
insulin levels (7).
There are several open questions about the manage-
ment of insulinoma, including the correlation among
insulin serum levels, control of the hypoglycemia, and
tumor response. In this paper, we report the oncological
history of a patient with inoperable, malignant insuli-
noma treated with everolimus.
The observation of the maintenance of drug activity
in controlling hypoglycemia irrespective of increasing
insulin levels and the resumption of the glycemic control,
which became refractory to drug administration after
temporary drug withdrawal, provide clues for reflection
on the mechanisms of everolimus activity and the best
schedule for drug administration in the management of
insulinoma.Case report
A 60-year-old man was diagnosed in July 2006 with liver
lesions; the cytology obtained from a fine needle aspi-
ration (FNA) indicated the presence of a metastatic lesion
from NE pancreatic tumor, G2; chromogranin A serum
levels were normal (73 ng/ml). A diagnosis of sporadic
insulinoma was made due to frequent episodes of
symptomatic hypoglycemia.
Owing to a positive single-photon emission compu-
terized tomography (SPECT) scintigraphy for the presence
of the receptors of somatostatin on pancreatic and liver
lesions, the patient started a treatment with octreotide
LAR 20 mg every 28 days, then increased after two yearshttp://www.edmcasereports.comPY ONLYto 30 mg every 28 days obtaining a disease stabilizationand glycemic control lasting for 3 years.
In May 2009, a liver progression was detected and
bevacizumab in association with metronomic capecita-
bine was introduced (phase 2 trial, no. NCT01203306).
The CT scan performed after 6 months showed a stable
disease. One month later, the patient suddenly developed
a symptomatic hypoglycemic episode during the night.
Blood measurements revealed low glucose levels
(30 mg/dl) and elevated insulin levels (O150 mUI/ml).
Treatment with i.v. glucose, prednisone, diazoxide, and
high-dose octreotide LAR (60 mg) was immediately insti-
tuted. Recombinant glucagon was administered on
demand. Despite this therapy, hypoglycemia was not
controlled and the patient was compelled to consume
frequent, small, carbohydrate-rich meals, and nocturnal
feeding. The patient weight increased by w8 kg in two
months, and in March 2010 he was subjected to radio-
labeled Lu-177 octreotate treatment.
After three cycles of radionuclide treatment, a CT scan
showed a stable disease but hypoglycemic symptoms were
still uncontrolled and the patient presented a cushingoid
habit caused by prednisone.
In November 2010, everolimus (10 mg daily) was
introduced in combination with radionuclide treatment.
Glycemic control improved rapidly leading to withdrawal
of diazoxide and prednisone. As reported in Fig. 1, glucose
levels were normalized during everolimus therapy even if
insulin levels remained persistently elevated.
Disease stabilization lasted till February 2012, when
a CT scan showed progression. At that time, insulin levels
increased consistently although the patient was not
symptomatic. Everolimus therapy was not interrupted
and hypoglycemia was controlled irrespective of disease
progression and further increase in insulin levels (Fig. 1).
In April 2012, the patient’s clinical conditions worsened
dramatically, resulting in remarkable lowering of blood
glucose and severe hypoglycemia, especially during
the night.
The patient was hospitalized; everolimus was discon-
tinued and treatment with repeated infusion of glucose
solution and glucagon (6 mg at 6.6 ml/h from 1100 to
0700 h by i.v. pump) was commenced.
Owing to the patient’s general worsening conditions,
with a low-grade renal failure, we decided not to use
streptozotocin but to start chemotherapy with weekly
carboplatin, area under the curve 2; it was introduced at
disease progression but was totally inefficacious and was
interrupted after 3 months. Everolimus was reintroduced
after a 2 month withdrawal and a resumption of serum2
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Figure 1
Serial evaluation of serum glucose (normal range, 70–110 mg/dl) and serum
insulin (normal range, 6–29 mUI/ml) in a patient with malignant insulinoma
before and during intermittent everolimus administration. The patient was
hospitalized during everolimus off periods to receive i.v. glucose,
prednisone, diazoxide and recombinant glucagon infusion.
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patient’s discharge from the hospital. The glycemic
control lasted for eight months, during which serum
insulin levels showed an increasing trend and the disease
demonstrated a slow progression.
New hypoglycemic episodes occurred in November
2012, necessitating hospitalization. Everolimus was again
stopped and pasireotide, a drug targeting four out of five
somatostatin receptors, was introduced but it was unable to
control the syndrome. Everolimus was reintroduced after a
2 months withdrawal and a glycemic control was immedi-
ately obtained, lasting for w2 months. At the beginning
of January 2013, the patient was hospitalized again owing
to acute kidney failure and he finally died after a few days,
36 months from the onset of the syndrome.Figure 2
(A) mTOR pathway blockade with everolimus. (B) mTOR-induced
gluconeogenesis, as a phenomenon independent of the control of
tumor growth.Discussion
The management of insulinoma is challenging. The use
of somatostatin analogs may not always be efficacious.
The inadequate control of insulin secretion by somato-
statin analogs is probably a consequence of the low
expression of SSTR2 and SSTR5 in insulinomas, which
also explains the reason for the low percentage of SPECT
scintigraphy-positive tumors. However, malignant insuli-
nomas, as opposed to benign ones, often express SSTR2 (8),
which can be targeted therapeutically by long-acting
somatostatin analogs (9). Accordingly, the patient
described herein, bearing malignant insulinoma, obtainedhttp://www.edmcasereports.comPY ONLYa long-lasting (three years) control of the syndrome witha somatostatin analog.
In patients with refractory syndrome to somatostatin
analogs, the control of hypoglycemia was very difficult
until two years ago when everolimus was introduced.
This drug is actually considered a valid therapeutic option
in the treatment of pancreatic NETs and is the reference
drug in the management of malignant insulinoma.
Several mechanisms are considered to explain the efficacy
of everolimus in controlling insulinoma-induced hypo-
glycemia. They include a decrease in insulin production
and/or an increase in peripheral insulin resistance. In our
case, everolimus controlled the glucose level in spite of the
high insulin level and disease progression. This underlines
that the drug may be effective in the management of3
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As the PI3K/AKT/MTOR pathway is essential for
hepatic gluconeogenesis (5), everolimus may counteract
hypoglycemia independent of its anti-tumor effect by
enhancing the expression of liver gluconeogenic enzymes
and nuclear recruitment of gluconeogenic transcriptional
regulators (Fig. 2).
In a recent preclinical study, FAM3A, a new cytokine-
like gene, activates the AKT/PI3K pathway despite insulin
levels, activating the hepatic gluconeogenesis in an
insulin-independent manner (10).
Everolimus reintroduction, after a temporary with-
drawal, was able to resume the glycemic control that
became refractory to the drug administration. Loss of
the control of hypoglycemia after an initial response to
everolimus, therefore, seems to be due to desensitization
or downregulation of mediators involved in the MTOR
pathway instead of a true resistance and can be reversed
after a period of treatment interruption.
Everolimus administration in our patient resulted
in disease stabilization lasting for six months, while the
control of glycemia persisted for 36 months with
intermittent administration.
In conclusion, despite the limitations of a single case
report, the clinical history described suggests that disease
progression and increasing levels of serum insulin may not
be considered the only criterion for discontinuing ever-
olimus therapy whenever hypoglycemia is controlled.
Preclinical and clinical studies are required to better
understand the pathways involved in glycemic control
after everolimus administration as well as the potential
efficacy of everolimus reintroduction after temporary
withdrawal.
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